Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

W5

Novel Small Molecule Inhibitors of Chikungunya Virus

Prof. Thierry Langer, University of Vienna, Dept. of Pharmaceutical Chemistry ; Prof. Ernst Urban, University of Vienna, Dept. of Pharmaceutical Chemistry ; Verena Battisti, University of Vienna, Dept. of Pharmaceutical Chemistry ; Dr Julia Moesslacher (neƩ Kirchebner), University of Vienna, Dept. of Pharmaceutical Chemistry and University of Innsbruck ; Dr Gerhard Puerstinger, University of Innsbruck; Rana Abdelnabi, KU Leuven; Leen Delang, KU Leuven; Dirk Jochmans, KU Leuven; Pieter Leyssen, KU Leuven; Arnaud Marchand, KU Leuven; Prof. Johan Neyts, KU Leuven

University of Vienna


Challenge

The prevention and treatment of viral diseases. Particularly those viral diseases against which no vaccines or pharmacotherapy is available.


Technology

The technology provides novel antiviral compounds, as well as derivatives thereof. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.


Commercial Opportunity

Applying an improved, reproducible synthesis route the performance of a scale-up and the synthesis of the compounds in large amounts, as well as formulation as pharmaceutical product is possible. Synthesis of compounds is done in line with GSP (good scientific practice) and using Standard Operating (Procedure). Small molecules are considered to have improved manufacturability, cost-efficiency and improved side effect profile compared to other antiviral compounds. The novel compounds are possibly suitable for the treatment of any kind of viral disease.


Development Status

Antiviral activity confirmed in cell culture, pharmacokinetic studies in mice


Patent Situation

PCT application WO2020221894A1 (published 2020-11-05)


Further Reading

Moesslacher J, Battisti V, Delang L, Neyts J, Abdelnabi R, PĆ¼rstinger G, Urban E, Langer T. Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. ACS Med Chem Lett. 2020 Mar 5;11(5):906-912


 

Novel Small Molecule Inhibitors of Chikungunya Virus